CSE New Listing - RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

RAMM Pharma Corp. (CSE:RAMM) is one of the latest new listings on the Canadian Securities Exchange. RAMM is one of the leaders in the field of cannabinoid pharmacology and product formulation for cannabis-derived prescription drugs and registered products.

For more information, please view the InvestmentPitch Media "video" which provides additional information on the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "RAMM" in the search box.



Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_li3rvmgn/New-Listing-RAMM-Pharma-Corp-CSERAMM

Founded in 1988 in Montevideo, Uruguay, RAMM is an established pharmaceutical and medical product business. In 2017 the company received approval for its first plant-derived cannabinoid pharmaceutical drug from Uruguay's Ministry of Health.

RAMM currently sells five cannabis based registered products commercially in Uruguay under two brands. It also has a pipeline of new products in various stages of approval and development. Its products have also been approved for use on a compassionate basis in 3 other Latin American countries and are in the application process at various stages of approval in several other countries.

Latin America alone has a population of 639 million, 350 million of which live in a jurisdiction with medical cannabis legislation in place or pending.

RAMM's formulation and manufacturing is conducted at its state-of-the-art Good Manufacturing Practices (GMP) certified cannabis formulation facility ideally situated within close proximity to an international airport and other export hubs. The facility totals approximately 36,600 square feet and features dedicated cannabis and medical product laboratories along with packaging capabilities and storage/distribution facilities.

The company is also in the process of establishing vertically integrated operations through the development of its large-scale cultivation facility. The company's approximately 7 hectare property, one of the largest greenhouse facilities in Uruguay, contains approximately 2 hectares of enclosed greenhouse facility with an additional 3 hectares of expansion space available.

In addition to RAMM's industry leading activities in the field of cannabinoid pharmaceuticals, RAMM also operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been in operations for 30 years.

Jack Burnett, CEO, stated: "Our public listing marks a significant milestone as RAMM continues to establish itself as a leader in the development and commercialization of cannabis-derived prescription drugs and registered products to meet the growing demand in Latin America and other jurisdictions globally. We are very pleased with the interest in our suite of products and look forward to increasing access to their therapeutic benefits as we continue to expand our product offerings, awareness and availability."

For more information, please visit the company's website www.RAMMpharma.com, contact Guillermo Delmonte, COO, at 484-474-0932 or by email at info@RAMMpharma.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community.

The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors. For more information please watch this video.

CONTACT:

InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49605

info